Truist Raises PT on Amneal Pharmaceuticals (AMRX) to $15 From $14

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is 1 of the champion performing pharma stocks successful 2025. On January 7, Truist raised the terms people connected Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) to $15 from $14 portion maintaining a Buy rating. The steadfast sees the affordable medicines taxable staying charismatic successful 2026.

In a abstracted development, Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) and mAbxience announced connected December 22 that the U.S. Food and Drug Administration approved its Biologics Licensing Applications for Boncresa™, a biosimilar referencing Prolia®, and Oziltus™, a biosimilar referencing XGEVA®. Denosumab is simply a monoclonal antibody wide utilized crossed oncology and osteoporosis-related conditions and is known to inhibit bony resorption. Amneal Pharmaceuticals, Inc.’s (NASDAQ:AMRX) concern with mAbxience entails that the erstwhile holds exclusive U.S. commercialization rights portion the second is liable for manufacturing and development.

Chirag and Chintu Patel, Co-Chief Executive Officers of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), stated that the summation of  2 denosumab biosimilars has expanded the company’s portfolio to 5 commercialized biosimilars, bolstering its presumption successful the rapidly processing domain. Management views biosimilars arsenic a sizeable semipermanent maturation vector successful the company’s Affordable Medicines segment.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is simply a medicine institution that provides pharmaceuticals. The company’s merchandise portfolio encompasses biosciences, specialty, generics, and merchandise catalog. Its operations are divided into the Generics, Specialty, and AvKARE segments.

While we admit the imaginable of AMRX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.